IMMUPHARMA PLC LS-01
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company's lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lup… Read more
Market Cap & Net Worth: IMMUPHARMA PLC LS-01 (25I)
IMMUPHARMA PLC LS-01 (F:25I) has a market capitalization of $31.22 Million (€30.41 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #23863 globally and #2610 in its home market, demonstrating a -0.82% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying IMMUPHARMA PLC LS-01's stock price €0.06 by its total outstanding shares 502723932 (502.72 Million).
IMMUPHARMA PLC LS-01 Market Cap History: 2017 to 2026
IMMUPHARMA PLC LS-01's market capitalization history from 2017 to 2026. Data shows change from $958.79 Million to $31.22 Million (-33.74% CAGR).
IMMUPHARMA PLC LS-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how IMMUPHARMA PLC LS-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 25I by Market Capitalization
Companies near IMMUPHARMA PLC LS-01 in the global market cap rankings as of March 18, 2026.
Key companies related to IMMUPHARMA PLC LS-01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
IMMUPHARMA PLC LS-01 Historical Marketcap From 2017 to 2026
Between 2017 and today, IMMUPHARMA PLC LS-01's market cap moved from $958.79 Million to $ 31.22 Million, with a yearly change of -33.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €31.22 Million | +2.54% |
| 2025 | €30.45 Million | +637.50% |
| 2024 | €4.13 Million | +3900.00% |
| 2023 | €103.21K | -98.00% |
| 2022 | €5.16 Million | -83.28% |
| 2021 | €30.86 Million | -53.10% |
| 2020 | €65.79 Million | -28.77% |
| 2019 | €92.37 Million | +49.17% |
| 2018 | €61.92 Million | -93.54% |
| 2017 | €958.79 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of IMMUPHARMA PLC LS-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $31.22 Million USD |
| MoneyControl | $31.22 Million USD |
| MarketWatch | $31.22 Million USD |
| marketcap.company | $31.22 Million USD |
| Reuters | $31.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.